Beam Therapeutics (BEAM) Stock Price, News & Analysis

Company Overview

Beam Therapeutics Inc. is a biotechnology company focused on developing genetic medicines using its proprietary base-editing technology. Unlike conventional gene-editing approaches that can make double-strand breaks in DNA, base editing is designed to make targeted changes to individual DNA letters, with the goal of treating diseases at their genetic source.

The company is developing both ex vivo and in vivo therapies. Its pipeline has included programs for sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency, glycogen storage disease type Ia and certain cancers. Beam’s work combines base-editing systems with delivery technologies intended to transport editors to specific cells or tissues.

Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was co-founded by scientists including David R. Liu and J. Keith Joung. The company conducts research and clinical development aimed at serving patients internationally and has entered collaborations and partnerships to advance its gene-editing platform and therapeutic programs.

Key Stats

• Today's Range: $23.75 to $24.97
• 50-Day Range: $23.10 to $31.03
• 52-Week Range: $20.23 to $38.26
• Volume: 1.22 million shs
• Average Volume: 1.90 million shs
• Market Capitalization: $2.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $49.00
• Consensus Rating: Moderate Buy

Beam Therapeutics Stock Analysis - MarketRank™

Beam Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 615th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Beam Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 10 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Beam Therapeutics has a consensus price target of $49.00, representing about 101.9% upside from its current price of $24.27.

Amount of Analyst Coverage

Beam Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Beam Therapeutics are expected to decrease in the coming year, from ($4.49) to ($5.05) per share.

Price to Book Value per Share Ratio

Beam Therapeutics has a P/B Ratio of 1.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

26.05% of the float of Beam Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Beam Therapeutics has a short interest ratio ("days to cover") of 12.59, which indicates bearish sentiment.

Change versus previous month

Short interest in Beam Therapeutics has recently increased by 0.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beam Therapeutics does not currently pay a dividend.

Dividend Growth

Beam Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

Beam Therapeutics has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Beam Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 8 people have searched for BEAM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

10 people have added Beam Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beam Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,296,475.00 in company stock.

Percentage Held by Insiders

3.80% of the stock of Beam Therapeutics is held by insiders.

Percentage Held by Institutions

99.68% of the stock of Beam Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BEAM
• CIK: 1745999
• Web: www.beamtx.com
• Phone: 857-327-8775
• Fax: N/A
• Employees: 540
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Beam Therapeutics: $49.00
• High Price Target: $80.00
• Low Price Target: $26.00
• Potential Upside/Downside: +101.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.69
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.86)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$79.99 million
• Net Margins: -54.75%
• Pretax Margin: -55.45%
• Return on Equity: -30.71%
• Return on Assets: -24.07%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 14.57
• Quick Ratio: 14.57

Sales & Book Value

• Annual Sales: $139.74 million
• Price / Sales: 17.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.20 per share
• Price / Book: 1.99

Miscellaneous

• Outstanding Shares: 103,290,000
• Free Float: 99,363,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 2.22